Pharmacology of Immunosuppressants Following Heart Transplantation
NCT ID: NCT01423552
Last Updated: 2011-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
NCT00812786
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
NCT01614665
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
NCT00157014
Aerosol Cyclosporine for Prevention of Lung Rejection
NCT00268515
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
NCT00135694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Post-heart transplant
All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous transplantation of another organ and already receiving chronic immunosuppressive therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nigel E. Drury
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nigel E. Drury
Specialist Registrar & Honorary Clinical Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert S Bonser, MD FRCS
Role: PRINCIPAL_INVESTIGATOR
University Hospital Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Basil Hetzel Institute for Medical Research
Adelaide, South Australia, Australia
Queen Elizabeth Hospital Birmingham
Birmingham, West Midlands, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRK4220
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.